scispace - formally typeset
Open AccessJournal ArticleDOI

Artemisinin Resistance in Plasmodium falciparum Malaria

Reads0
Chats0
TLDR
The overall median clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours in Wang Pha (P<0.001) in each of the two locations as discussed by the authors.
Abstract
We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P = 0. 31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups. CONCLUSIONS P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy

TL;DR: The mechanisms underlying parasite clearance after artemisinin treatment are reviewed and how these might relate to in vitro methods to assay for resistance are revisited.
Journal ArticleDOI

Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity

TL;DR: This study synthesized a series of chemical analogs that reduce host cell toxicity while maintaining blood-stage and gametocytocidal antimalarial activity and proteasome inhibition, and describes a promising new class of antimalaria compound based on the carmaphycin B scaffold.
Journal ArticleDOI

Reliability of Antimalarial Sensitivity Tests Depends on Drug Mechanisms of Action

TL;DR: Two isotopic tests, two enzyme-linked immunosorbent assays (ELISA) and the SYBR green I fluorescence-based assay are applied to test artesunate and chloroquine, the metabolic inhibitors atovaquone and pyrimethamine, the authors' fast-acting choline analog T3/SAR97276, and doxycycline, which has a delayed death profile.
References
More filters
Journal ArticleDOI

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

TL;DR: Artemisinins are potent and rapidly acting antimalarial drugs, and their widespread use for treating patients with Plasmodium falciparum malaria raises the question of emerging drug resistance.
Journal ArticleDOI

Artemisinins target the SERCA of Plasmodium falciparum

TL;DR: It is shown that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor).
Journal ArticleDOI

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

TL;DR: Artesunate should become the treatment of choice for severe falciparum malaria in adults because it is more rapidly acting than intravenous quinine in terms of parasite clearance and is simpler to administer.
Journal ArticleDOI

Qinghaosu (artemisinin): the price of success.

TL;DR: Artemisinin combination treatments are now first-line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries and a global subsidy would make these drugs more affordable and available.
Related Papers (5)

Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Elizabeth A. Ashley, +82 more